Nucleon small biotech company whose first potential product is on the verge of clinical trials. Nucleon before clinical trials can begin, however, its leaders must decide how and where to produce the product. Three options are currently proposed: 1) to establish a pilot plant in the house, 2) contract for the production side, 3) license to develop, manufacture, and marketing rights to corporate partners. Allows you to discuss a number of manufacturing strategy issues related to R & D-intensive entrepreneurial firms. A key issue is the strategic value in their own production company, which competes mainly on very specific and specialized R & D capabilities. "Hide
by Gary P. Pisano Source: Harvard Business School 16 pages. Publication Date: November 21, 1991. Prod. # 692 041-PDF-ENG
Related Case Solutions & Analyses:
Jewellworld.com–Online Jewelry Shopping in China
Types of Processes
Congoleum Corp.
General Electric: Strategic Position–1981
Corning Glass Works International (C1)
Pepsi and bricks
Managing Production quotas in a cartel market for maximization of earnings
Fortis Industries, Inc. (A), Spanish Version
vineyard vines and The Brotherhood of the Traveling Pants
Oversight Systems
